For immediate release |
21 January 2011 |
Alliance Pharma plc
TR-1: Notification of major interest in shares
1. Identity of the issuer or the underlying issuer |
Alliance Pharma plc |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
|
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
On market transfer between direct and indirect funds |
YES |
||
3. Full name of person(s) subject to the |
Aviva plc and its subsidiaries |
|||
4. Full name of shareholder(s) |
Registered Holder:
BNY Norwich Union Nominees Limited 2,161,425*
Chase (GA Group) Nominees Limited 13,192,709*
CUIM Nominee Limited 2,031,377*
*denotes direct interest
BNP Paribas - London 1,546,572
Chase Nominees Limited 5,384,672
|
|||
5. Date of the transaction and date on |
20 January 2011 |
|||
6. Date on which issuer notified: |
21 January 2011 |
|||
7. Threshold(s) that is/are crossed or |
5% to 7% Change at Direct Interest Level |
|||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights |
||||||||||||
Direct |
Direct |
Indirect |
Direct |
Indirect |
||||||||||||
GB0031030819 |
Direct: 13,962,660 (5.94%) Indirect: 10,354,095 (4.41%) |
Direct: 13,962,660 (5.94%) Indirect: 10,354,095 (4.41%) |
24,316,755 |
17,385,511 |
6,931,244 |
7.36% |
2.93% |
|||||||||
|
||||||||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights
|
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
24,316,755 |
10.29% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See section 4 |
|
11. Number of voting rights proxy holder will cease |
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
||
|
|
|
14. Contact name: |
Neil Whittaker, Aviva plc |
|
15. Contact telephone number: |
01603 684420 |
|